Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • The unmet medical need for Trypanosoma cruzi-infected patients: Monitoring the disease status
  • Setting our sights on infectious diseases
  • Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi

RSS PRESS RELEASES

  • HIV treatment for children to be produced for under one dollar a day
  • Public-private partnership launched to develop new drugs for roundworm infections
  • Research for new drugs against neglected diseases and malaria in Brazil to receive funding boost totaling BRL 43.5 million

RSS NEWS

  • Innovating for kids with HIV
  • DNDi and partners hold seminar in Mexico aimed at improving access to diagnostics and treatment of Chagas disease
  • DNDi appoints new Directors of Research & Development and Strategy & Operations

RSS IN THE MEDIA

  • The East African: “Children to no longer bear with bitter ARVs”
  • Xinhua: “African scientists give hope to HIV positive infants amid improved treatment regime”
  • The Sangai Express: “A new formulation of life-saving medicines on the anvil for children living with HIV”

RSS EVENTS

  • 5th National Hepatitis Conference Malaysia
  • ICID 2020
  • 6th Annual World Open Innovation Conference

RSS Scientific Articles

  • The unmet medical need for Trypanosoma cruzi-infected patients: Monitoring the disease status
  • Setting our sights on infectious diseases
  • Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi
  • A four-step process for building sustainable access to diagnosis and treatment of Chagas disease

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

DNDi's social mission ratio

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close